About Aromatase
Aromatase (CYP19A1) is a protein
from Homo sapiens identified by UniProt accession
P11511, 503 residues long.
MolForge cross-references it against 0 known binders and
1,037 disease associations.
Target properties
| Protein name | Aromatase |
| UniProt accession | P11511 |
| Gene | CYP19A1 |
| Organism | Homo sapiens |
| Length | 503 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (1037)
Diseases linked to this target (Open Targets).
- aromatase deficiency · score 0.77
- breast cancer · score 0.63
- breast carcinoma · score 0.61
- breast neoplasm · score 0.59
- neoplasm · score 0.56
- infertility · score 0.56
- heel bone mineral density · score 0.55
- body height · score 0.52
- endometrial carcinoma · score 0.52
- estradiol measurement · score 0.52
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11511-F1 | alphafold | PREDICTED | 91.38 | — |
Amino-acid sequence (503 residues)
MVLEMLNPIH YNITSIVPEA MPAATMPVLL LTGLFLLVWN YEGTSSIPGP GYCMGIGPLI SHGRFLWMGI GSACNYYNRV YGEFMRVWIS GEETLIISKS SSMFHIMKHN HYSSRFGSKL GLQCIGMHEK GIIFNNNPEL WKTTRPFFMK ALSGPGLVRM VTVCAESLKT HLDRLEEVTN ESGYVDVLTL LRRVMLDTSN TLFLRIPLDE SAIVVKIQGY FDAWQALLIK PDIFFKISWL YKKYEKSVKD LKDAIEVLIA EKRRRISTEE KLEECMDFAT ELILAEKRGD LTRENVNQCI LEMLIAAPDT MSVSLFFMLF LIAKHPNVEE AIIKEIQTVI GERDIKIDDI QKLKVMENFI YESMRYQPVV DLVMRKALED DVIDGYPVKK GTNIILNIGR MHRLEFFPKP NEFTLENFAK NVPYRYFQPF GFGPRGCAGK YIAMVMMKAI LVTLLRRFHV KTLQGQCVES IQKIHDLSLH PDETKNMLEM IFTPRNSDRC LEH
Explore Aromatase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets